Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Importance

Abiraterone acetate and enzalutamide are recommended as preferred treatments for metastatic castration-resistant prostate cancer (mCRPC), but differences in their relative efficacy are unclear due to a lack of head-to-head clinical trials. Clear guidance is needed for making informed mCRPC therapeutic choices.

Objective

To compare clinical outcomes in patients with mCRPC treated with abiraterone acetate or enzalutamide.

Design, setting, and participants

This retrospective, multicenter cohort study included patients with mCRPC in the US Department of Veterans Affairs health care system who initiated treatment with abiraterone acetate or enzalutamide between January 1, 2014, and October 30, 2022.

Exposures

Abiraterone acetate or enzalutamide.

Main o

SUBMITTER: La J 

PROVIDER: S-EPMC11329885 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature